Disease-modifying therapeutic strategies in osteoarthritis: current status and future directions

참고문헌 (147)

1. Kim, J. H., "Regulation of the catabolic cascade in osteoarthritis by the zincZIP8-MTF1 axis", Cell, 156, pp.730~743 (2014)
2. Kang, D., "Stress-activated miR-204 governs senescent phenotypes of chondrocytes to promote osteoarthritis development", Sci. Transl. Med., 11, pp.eaar6659~ (2019)
3. Kim, S., "Tankyrase inhibition preserves osteoarthritic cartilage by coordinating cartilage matrix anabolism via effects on SOX9 PARylation", Nat. Commun, 10, pp.4898~ (2019)
4. Mobasheri, A., "The role of metabolism in the pathogenesis of osteoarthritis", Nat. Rev. Rheumatol, 13, pp.302~311 (2017)
5. Goldring, S. R., "Changes in the osteochondral unit during osteoarthritis : structure, function and cartilage-bone crosstalk", Nat. Rev. Rheumatol, 12, pp.632~644 (2016)
6. Crofford, L. J., "Use of NSAIDs in treating patients with arthritis", Arthritis Res. Ther, 15, pp.S2~ (2013)
7. Frallonardo, P., "Basic calcium phosphate and pyrophosphate crystals in early and late osteoarthritis : relationship with clinical indices and inflammation", Clin. Rheumatol, 37, pp.2847~2853 (2018)
8. 김현경, "Epigenetic Regulation of Chondrocyte Catabolism and Anabolism in Osteoarthritis", Molecules and Cells, 38(8), pp.677~684 (2015), 한국분자세포생물학회[DOI]
9. Chow, Y. Y., "The role of inflammation in the pathogenesis of osteoarthritis", Mediators Inflamm, 2020, pp.8293921~ (2020)
10. Martel-Pelletier, J., "Osteoarthritis", Nat. Rev. Dis. Prim, 2, pp.16072~ (2016)
11. El Mansouri, F. E., "Contribution of H3K4 methylation by SET-1A to interleukin-1-induced cyclooxygenase 2 and inducible nitric oxide synthase expression in human osteoarthritis chondrocytes", Arthritis Rheumatol, 63, pp.168~179 (2011)
12. Hardy, M. M., "Cyclooxygenase 2-dependent prostaglandin E2 modulates cartilage proteoglycan degradation in human osteoarthritis explants", Arthritis Rheumatol, 46, pp.1789~1803 (2002)
13. Jones, S. W., "Mitogen-activated protein kinase-activated protein kinase 2(MK2)modulates key biological pathways associated with OA disease pathology", Osteoarthr. Cartil, 17, pp.124~131 (2009)
14. Goldring, M. B., "Inflammation in osteoarthritis", Curr. Opin. Rheumatol., 23, pp.471~478 (2011)
15. Chevalier, X., "Intraarticular injection of anakinra in osteoarthritis of the knee : a multicenter, randomized, double-blind, placebo-controlled study", Arthritis Rheumatol, 61, pp.344~352 (2009)
16. Cohen, S. B., "A randomized, double-blind study of AMG 108(a fully human monoclonal antibody to IL-1R1)in patients with osteoarthritis of the knee", Arthritis Res. Ther, 13, pp.R125~ (2011)
17. Kloppenburg, M., "Phase IIa, placebo-controlled, randomised study of lutikizumab, an anti-interleukin-1α and anti-interleukin-1β dual variable domain immunoglobulin, in patients with erosive hand osteoarthritis", Ann. Rheum. Dis, 78, pp.413~420 (2019)
18. Fleischmann, R. M., "A phase II trial of lutikizumab, an anti-interleukin-1α", βdual variable domain immunoglobulin, in knee osteoarthritis patients with synovitis, 2019, pp.71, 1056~1069
19. Aitken, D., "A randomised double-blind placebo-controlled crossover trial of HUMira(adalimumab)for erosive hand OsteoaRthritis—the HUMOR trial", Osteoarthr. Cartil, 26, pp.880~887 (2018)
20. Kloppenburg, M., "Etanercept in patients with inflammatory hand osteoarthritis(EHOA) : a multicentre, randomised, double-blind, placebocontrolled trial", Ann. Rheum. Dis, 77, pp.1757~1764 (2018)
21. Heinegard, D., "The role of the cartilage matrix in osteoarthritis", Nat. Rev. Rheumatol, 7, pp.50~56 (2011)
22. Loeser, R. F., "Ageing and the pathogenesis of osteoarthritis", Nat. Rev. Rheumatol, 12, pp.412~420 (2016)
23. Pap, T., "Cartilage damage in osteoarthritis and rheumatoid arthritis-two unequal siblings", Nat. Rev. Rheumatol, 11, pp.606~615 (2015)
24. Wang, M., "MMP13 is a critical target gene during the progression of osteoarthritis", Arthritis Res. Ther, 15, pp.R5~ (2013)
25. Kamekura, S., "Osteoarthritis development in novel experimental mouse models induced by knee joint instability", Osteoarthr. Cartil, 13, pp.632~641 (2005)
26. Little, C. B., "Matrix metalloproteinase 13-deficient mice are resistant to osteoarthritic cartilage erosion but not chondrocyte hypertrophy or osteophyte development", Arthritis Rheumatol, 60, pp.3723~3733 (2009)
27. Sabatini, M., "Effect of inhibition of matrix metalloproteinases on cartilage loss in vitro and in a guinea pig model of osteoarthritis", Arthritis Rheumatol, 52, pp.171~180 (2005)
28. Johnson, A. R., "Discovery and characterization of a novel inhibitor of matrix metalloprotease-13 that reduces cartilage damage in vivo without joint fibroplasia side effects", J. Biol. Chem, 282, pp.27781~27791 (2007)
29. Krzeski, P., "Development of musculoskeletal toxicity without clear benefit after administration of PG-116800, a matrix metalloproteinase inhibitor, to patients with knee osteoarthritis : a randomized, 12-month, double-blind, placebo-controlled study", Arthritis Res. Ther, 9, pp.R109~ (2007)
30. Holmbeck, K., "MT1-MMP-deficient mice develop dwarfism, osteopenia, arthritis, and connective tissue disease due to inadequate collagen turnover", Cell, 99, pp.81~92 (1999)
31. Baragi, V. M., "A new class of potent matrix metalloproteinase 13 inhibitors for potential treatment of osteoarthritis : Evidence of histologic and clinical efficacy without musculoskeletal toxicity in rat models", Arthritis Rheumatol, 60, pp.2008~2018 (2009)
32. Glasson, S. S., "Deletion of active ADAMTS5 prevents cartilage degradation in a murine model of osteoarthritis", Nature, 434, pp.644~648 (2005)
33. Stanton, H., "ADAMTS5 is the major aggrecanase in mouse cartilage in vivo and in vitro", Nature, 434, pp.648~652 (2005)
34. Clement-Lacroix, P., "Glpg1972 : a potent, selective, orally available adamts-5inhibitor for the treatment of OA", Osteoarthr. Cartil, 25, pp.S58~S59 (2017)
35. Deckx, H. M., "A safety, tolerability, pharmacokinetics(Pk)and pharmacodynamics(Pd)study with increasing oral doses of Glpg1972 administered daily for 29 days shows a strong biomarker effect in patients with knee and", or hip OA, 2018, pp.77, 795~796
36. van der Aar, E. M., "Adamts-5 inhibitor Glpg1972, a potential new treatment in osteoarthritis, shows favorable safety, pharmacokinetics and pharmacodynamics in healthy subjects", Osteoarthr. Cartil, 26, pp.S310~S310 (2018)
37. "IntradoGlobeNewswire" (2020)[URL]
38. Santamaria, S., "ADAMTS-5 : a difficult teenager turning 20", Int. J. Exp. Pathol, 101, pp.4~20 (2020)
39. Siebuhr, A. S., "The anti-ADAMTS-5 nanobody((R))M6495 protects cartilage degradation ex vivo", Int. J. Mol. Sci, 21, pp.5992~ (2020)
40. Guehring, H., "Safety, tolerability, pharmacokinetics and pharmacodynamics of single ascending doses of the anti-ADAMTS-5 nanobody(R), M6495, in healthy male subjects : a phase I, placebo-controlled, first-in-human study", Arthritis Rheumatol, 71, pp.2175~ (2019)
41. Joyce, J. A., "Cathepsin cysteine proteases are effectors of invasive growth and angiogenesis during multistage tumorigenesis", Cancer Cell, 5, pp.443~453 (2004)
42. Turk, V., "Lysosomal cathepsins : structure, role in antigen processing and presentation, and cancer", Adv. Enzym. Regul, 42, pp.285~303 (2002)
43. Bogyo, M., "Selective targeting of lysosomal cysteine proteases with radiolabeled electrophilic substrate analogs", Chem. Biol, 7, pp.27~38 (2000)
44. Patel, S., "Cathepsins: proteases that are vital for survival but can also be fatal", Biomed. Pharmacother., 105, pp.526~532 (2018)
45. Aguda, A. H., "Structural basis of collagen fiber degradation by cathepsin K", Proc. Natl Acad. Sci. USA, 111, pp.17474~17479 (2014)
46. Kozawa, E., "Increased expression and activation of cathepsin K in human osteoarthritic cartilage and synovial tissues", J. Orthop. Res, 34, pp.127~134 (2016)
47. Ben-Aderet, L., "Detecting cathepsin activity in human osteoarthritis via activity-based probes", Arthritis Res. Ther, 17, pp.69~ (2015)
48. Connor, J. R., "Protective effects of a cathepsin K inhibitor, SB-553484, in the canine partial medial meniscectomy model of osteoarthritis", Osteoarthr. Cartil, 17, pp.1236~1243 (2009)
49. Hayami, T., "Inhibition of cathepsin K reduces cartilage degeneration in the anterior cruciate ligament transection rabbit and murine models of osteoarthritis", Bone, 50, pp.1250~1259 (2012)
50. Nwosu, L. N., "Analgesic effects of the cathepsin K inhibitor L-006235 in the monosodium iodoacetate model of osteoarthritis pain", Pain Rep, 3, pp.e685~ (2018)
51. McDougall, J. J., "Cathepsin K inhibition reduces CTXII levels and joint pain in the guinea pig model of spontaneous osteoarthritis", Osteoarthr. Cartil., 18, pp.1355~1357 (2010)
52. Lindstrom, E., "Nonclinical and clinical pharmacological characterization of the potent and selective cathepsin K inhibitor MIV-711", J. Transl. Med, 16, pp.125~ (2018)
53. Conaghan, P. G., "Six months’ treatment with Miv-711, a novel cathepsin K inhibitor induces osteoarthritis structure modification : results from a randomized double-blind placebo-controlled phase IIA trial", Osteoarthr. Cartil, 26, pp.S25~S26 (2018)
54. Conaghan, P. G., "Safety and efficacy of six months’ open label extension post-RCT using the novel cathepsin K inhibitor MIV-711 in patients with knee osteoarthritis", Osteoarthr. Cartil, 27, pp.S501~S502 (2019)
55. Conaghan, P. G., "Disease-modifying effects of a novel cathepsin K inhibitor in osteoarthritis : a randomized controlled trial", Ann. Intern. Med, 172, pp.86~95 (2020)
56. Nusse, R., "Wnt", β-catenin signaling, disease, and emerging therapeutic modalities, 2017, pp.169, 985~999
57. Lories, R. J., "To Wnt or not to Wnt : the bone and joint health dilemma", Nat. Rev. Rheumatol, 9, pp.328~339 (2013)
58. Lambert, C., "Gene expression pattern of cells from inflamed and normal areas of osteoarthritis synovial membrane", Arthritis Rheumatol, 66, pp.960~968 (2014)
59. Nakamura, Y., "Expression profiles and functional analyses of Wnt-related genes in human joint disorders", Am. J. Pathol, 167, pp.97~105 (2005)
60. Nguyen, D. X., "WNT", TCF signaling through LEF1 and HOXB9 mediates lung adenocarcinoma metastasis, 2009, pp.138, 51~62
61. Anastas, J. N., "WNT signalling pathways as therapeutic targets in cancer", Nat. Rev. Cancer, 13, pp.11~26 (2013)
62. Hartmann, C., "Wnt-14 plays a pivotal role in inducing synovial joint formation in the developing appendicular skeleton", Cell, 104, pp.341~351 (2001)
63. Tamamura, Y., "Developmental regulation of Wnt", β-catenin signals is required for growth plate assembly, cartilage integrity, and endochondral ossification, 2005, pp.280, 19185~19195
64. Day, T. F., "Wnt", β-catenin signaling in mesenchymal progenitors controls osteoblast and chondrocyte differentiation during vertebrate skeletogenesis, 2005, pp.8, 739~750
65. Kim, S. J., "β-Catenin regulates expression of cyclooxygenase-2 in articular chondrocytes", Biochem. Biophys. Res. Commun, 296, pp.221~226 (2002)
66. Corr, M., "Wnt-β-catenin signaling in the pathogenesis of osteoarthritis", Nat. Clin. Pract. Rheumatol, 4, pp.550~556 (2008)
67. Lu, B., "Wnt drug discovery : weaving through the screens, patents and clinical trials", Cancers(Basel), 8, pp.82~ (2016)
68. Kahn, M., "Can we safely target the WNT pathway?", Nat. Rev. Drug Discov., 13, pp.513~532 (2014)
69. Deshmukh, V., "A small-molecule inhibitor of the Wnt pathway(SM04690)as a potential disease modifying agent for the treatment of osteoarthritis of the knee", Osteoarthr. Cartil, 26, pp.18~27 (2018)
70. Deshmukh, V., "Modulation of the Wnt pathway through inhibition of CLK2and DYRK1A by lorecivivint as a novel, potentially disease-modifying approach for knee osteoarthritis treatment", Osteoarthr. Cartil, 27, pp.1347~1360 (2019)
71. Yazici, Y., "A novel Wnt pathway inhibitor, SM04690, for the treatment of moderate to severe osteoarthritis of the knee : results of a 24-week, randomized, controlled, phase 1 study", Osteoarthr. Cartil, 25, pp.1598~1606 (2017)
72. Yazici, Y., "Lorecivivint, a novel intraarticular CDC-like kinase 2 and dualspecificity tyrosine phosphorylation-regulated kinase 1A inhibitor and Wnt pathway modulator for the treatment of knee osteoarthritis : a phase II randomized trial", Arthritis Rheumatol, 72, pp.1694~1706 (2020)
73. Yazici, Y., "Efficacy and safety from a phase 2b trial of Sm04690, a novel, intra-articular, Wnt pathway inhibitor for the treatment of osteoarthritis of the knee", Osteoarthr. Cartil, 27, pp.S503~S503 (2019)
74. Johnson, K., "A stem cell-based approach to cartilage repair", Science, 336, pp.717~721 (2012)
75. Johnson, K. A., "Development of Ka34 as a cartilage regenerative therapy for osteoarthritis", Osteoarthr. Cartil, 28, pp.S518~S518 (2020)
76. Scotti, C., "LNA043, a novel cartilage regenerative treatment for osteoarthritis : results from a first-in-human trial in patients with knee osteoarthritis", Arthritis Rheumatol, 72, pp.1485~ (2020)
77. Jiang, S., "ANGPTL3 : a novel biomarker and promising therapeutic target", J. Drug Target, 27, pp.876~884 (2019)
78. Malfait, A. M., "Towards a mechanism-based approach to pain management in osteoarthritis", Nat. Rev. Rheumatol, 9, pp.654~664 (2013)
79. Miller, R. J., "Cytokine and chemokine regulation of sensory neuron function", Handb. Exp. Pharm, 194, pp.417~449 (2009)
80. Latremoliere, A., "Central sensitization : a generator of pain hypersensitivity by central neural plasticity", J. Pain, 10, pp.895~926 (2009)
81. Fu, K., "Osteoarthritis: the genesis of pain", Rheumatology (Oxf.), 57, pp.iv43~iv50 (2018)
82. Arendt-Nielsen, L., "Sensitization in patients with painful knee osteoarthritis", Pain, 149, pp.573~581 (2010)
83. Lane, N. E., "Tanezumab for the treatment of pain from osteoarthritis of the knee", N. Engl. J. Med, 363, pp.1521~1531 (2010)
84. Lolignier, S., "Mechanical allodynia", Pflug. Arch, 467, pp.133~139 (2015)
85. Wise, B. L., "The evolution of nerve growth factor inhibition in clinical medicine", Nat. Rev. Rheumatol, 17, pp.34~46 (2021)
86. Caterina, M. J., "A capsaicinreceptor homologue with a high threshold for noxious heat", Nature, 398, pp.436~441 (1999)
87. Huang, J., "Inflammatory pain : the cellular basis of heat hyperalgesia", Curr. Neuropharmacol, 4, pp.197~206 (2006)
88. Stoppiello, L. A., "Structural associations of symptomatic knee osteoarthritis", Arthritis Rheumatol, 66, pp.3018~3027 (2014)
89. Walsh, D. A., "Angiogenesis and nerve growth factor at the osteochondral junction in rheumatoid arthritis and osteoarthritis", Rheumatology (Oxf.), 49, pp.1852~1861 (2010)
90. Abdiche, Y. N., "Probing the binding mechanism and affinity of tanezumab, a recombinant humanized anti-NGF monoclonal antibody, using a repertoire of biosensors", Protein Sci., 17, pp.1326~1335 (2008)
91. Berenbaum, F., "Subcutaneous tanezumab for osteoarthritis of the hip or knee : efficacy and safety results from a 24-week randomised phase III study with a 24-week follow-up period", Ann. Rheum. Dis, 79, pp.800~810 (2020)
92. Yu, Y., "Safety of low-dose tanezumab in the treatment of hip or knee osteoarthritis: a systemic review and meta-analysis of randomized phase III clinical trials", Pain. Med., 22, pp.585~595 (2021)
93. Tiseo, P. J., "Fasinumab(REGN475), an antibody against nerve growth factor for the treatment of pain : results from a double-blind, placebo-controlled exploratory study in osteoarthritis of the knee", Pain, 155, pp.1245~1252 (2014)
94. Dakin, P., "The efficacy, tolerability, and joint safety of fasinumab in osteoarthritis pain : a phase IIb", III double-blind, placebo-controlled, randomized clinical trial, 2019, pp.71, 1824~1834
95. Sanga, P., "Efficacy, safety, and tolerability of fulranumab, an anti-nerve growth factor antibody, in the treatment of patients with moderate to severe osteoarthritis pain", Pain, 154, pp.1910~1919 (2013)
96. Mayorga, A. J., "Efficacy and safety of fulranumab as monotherapy in patients with moderate to severe, chronic knee pain of primary osteoarthritis: a randomised, placebo- and active-controlled trial", Int. J. Clin. Pract., 70, pp.493~505 (2016)
97. Sanga, P., "Long-term safety and efficacy of fulranumab in patients with moderate-to-severe osteoarthritis pain : a phase II randomized, double-blind, placebo-controlled extension study", Arthritis Rheumatol, 69, pp.763~773 (2017)
98. Kelly, K. M., "Safety and efficacy of fulranumab in osteoarthritis of the hip and knee : results from four early terminated phase III randomized studies", Curr. Med. Res. Opin, 35, pp.2117~2127 (2019)
99. Kang, C., "The DNA damage response induces inflammation and senescence by inhibiting autophagy of GATA4", Science, 349, pp.aaa5612~ (2015)
100. Jeon, O. H., "Local clearance of senescent cells attenuates the development of post-traumatic osteoarthritis and creates a pro-regenerative environment", Nat. Med, 23, pp.775~781 (2017)
101. Zhang, M., "Induced superficial chondrocyte death reduces catabolic cartilage damage in murine posttraumatic osteoarthritis", J. Clin. Invest, 126, pp.2893~2902 (2016)
102. 강찬희, "Senolytics and Senostatics: A Two-Pronged Approach to Target Cellular Senescence for Delaying Aging and Age-Related Diseases", Molecules and Cells, 42(12), pp.821~827 (2019), 한국분자세포생물학회[DOI]
103. Cao, X., "Intraarticular senescent chondrocytes impair the cartilage regeneration capacity of mesenchymal stem cells", Stem Cell Res. Ther, 10, pp.86~ (2019)
104. Fuhrmann-Stroissnigg, H., "Identification of HSP90 inhibitors as a novel class of senolytics", Nat. Commun, 8, pp.422~ (2017)
105. Dai, H., "Eliminating senescent chondrogenic progenitor cells enhances chondrogenesis under intermittent hydrostatic pressure for the treatment of OA", Stem Cell Res. Ther, 11, pp.199~ (2020)
106. Siebelt, M., "Hsp90 inhibition protects against biomechanically induced osteoarthritis in rats", Arthritis Rheumatol, 65, pp.2102~2112 (2013)
107. Yang, H., "Navitoclax (ABT263) reduces inflammation and promotes chondrogenic phenotype by clearing senescent osteoarthritic chondrocytes in osteoarthritis", Aging (Albany NY), 12, pp.12750~12770 (2020)
108. Wu, D., "Relevance of the p53-MDM2 axis to aging", Cell Death Differ, 25, pp.169~179 (2018)
109. Hsu, B., "Safety, tolerability, pharmacokinetics, and clinical outcomes following single-dose IA administration of UBX0101, a senolytic MDM2", p53 interaction inhibitor, in patients with knee OA, 2019, pp.71, L05~
110. Faust, H. J., "IL-17 and immunologically induced senescence regulate response to injury in osteoarthritis", J. Clin. Invest, 130, pp.5493~5507 (2020)
111. Miyaki, S., "Macro view of microRNA function in osteoarthritis", Nat. Rev. Rheumatol, 8, pp.543~552 (2012)
112. Santini, P., "The inflammatory circuitry of miR-149 as a pathological mechanism in osteoarthritis", Rheumatol. Int, 34, pp.711~716 (2014)
113. Yan, S., "MicroRNA-34a affects chondrocyte apoptosis and proliferation by targeting the SIRT1", p53 signaling pathway during the pathogenesis of osteoarthritis, 2016, pp.38, 201~209
114. Akhtar, N., "MicroRNA-27b regulates the expression of matrix metalloproteinase 13 in human osteoarthritis chondrocytes", Arthritis Rheumatol, 62, pp.1361~1371 (2010)
115. Miyaki, S., "MicroRNA-140 plays dual roles in both cartilage development and homeostasis", Genes Dev, 24, pp.1173~1185 (2010)
116. Jiang, S., "Noncoding RNAs : new regulatory code in chondrocyte apoptosis and autophagy", Wiley Interdiscip. Rev. RNA, 11, pp.e1584~ (2020)
117. Wu, Y., "The therapeutic potential and role of miRNA, lncRNA, and circRNA in osteoarthritis", Curr. Gene Ther, 19, pp.255~263 (2019)
118. Lieberman, J., "Tapping the RNA world for therapeutics", Nat. Struct. Mol. Biol, 25, pp.357~364 (2018)
119. Zhou, L. B., "Short interfering RNA(siRNA)-based therapeutics for cartilage diseases", Regen. Eng. Transl. Med, 7, pp.283~290 (2020)
120. Kole, R., "RNA therapeutics: beyond RNA interference and antisense oligonucleotides", Nat. Rev. Drug Discov., 11, pp.125~140 (2012)
121. Setten, R. L., "The current state and future directions of RNAi-based therapeutics", Nat. Rev. Drug Discov, 18, pp.421~446 (2019)
122. Hoshi, H., "Effect of inhibiting MMP13 and ADAMTS5 by intra-articular injection of small interfering RNA in a surgically induced osteoarthritis model of mice", Cell Tissue Res, 368, pp.379~387 (2017)
123. Marcu, K. B., "NF-κB signaling : multiple angles to target OA", Curr. Drug Targets, 11, pp.599~613 (2010)
124. Rigoglou, S., "The NF-κB signalling pathway in osteoarthritis", Int. J. Biochem. Cell Biol, 45, pp.2580~2584 (2013)
125. Yan, H., "Suppression of NF-κB activity via nanoparticle-based siRNA delivery alters early cartilage responses to injury", Proc. Natl Acad. Sci. USA, 113, pp.E6199~E6208 (2016)
126. Yang, S., "Hypoxia-inducible factor-2 α is a catabolic regulator of osteoarthritic cartilage destruction", Nat. Med, 16, pp.687~693 (2010)
127. Saito, T., "Transcriptional regulation of endochondral ossification by HIF-2αduring skeletal growth and osteoarthritis development", Nat. Med, 16, pp.678~686 (2010)
128. Pi, Y., "Intra-articular delivery of anti-Hif-2α siRNA by chondrocyte-homing nanoparticles to prevent cartilage degeneration in arthritic mice", Gene Ther, 22, pp.439~448 (2015)
129. Rinaldi, C., "Antisense oligonucleotides: the next frontier for treatment of neurological disorders", Nat. Rev. Neurol., 14, pp.9~21 (2018)
130. Bierma-Zeinstra, S. M., "Osteoarthritis subpopulations and implications for clinical trial design", Arthritis Res. Ther, 13, pp.213~ (2011)
131. Felson, D. T., "Identifying different osteoarthritis phenotypes through epidemiology", Osteoarthr. Cartil, 18, pp.601~604 (2010)
132. Deveza, L. A., "Phenotypes of osteoarthritis : current state and future implications", Clin. Exp. Rheumatol, 37, pp.64~72 (2019)
133. Zhou, X., "MiR-132-3p regulates ADAMTS-5 expression and promotes chondrogenic differentiation of rat mesenchymal stem cells", J. Cell Biochem, 119, pp.2579~2587 (2018)
134. Qian, J., "miR-107 affects cartilage matrix degradation in the pathogenesis of knee osteoarthritis by regulating caspase-1", J. Orthop. Surg. Res, 16, pp.40~ (2021)
135. Ren, T., "MiR-140-3p ameliorates the progression of osteoarthritis via targeting CXCR4", Biol. Pharm. Bull, 43, pp.810~816 (2020)
136. Wang, Z., "miR-140-5p", miR-149 affects chondrocyte proliferation, apoptosis, and autophagy by targeting FUT1 in osteoarthritis, 2018, pp.41, 959~971
137. Xue, H., "miR-93-5p attenuates IL-1β-induced chondrocyte apoptosis and cartilage degradation in osteoarthritis partially by targeting TCF4", Bone, 123, pp.129~136 (2019)
138. Zhong, G., "miRNA-335-5p relieves chondrocyte inflammation by activating autophagy in osteoarthritis", Life Sci, 226, pp.164~172 (2019)
139. Ji, Q., "Cryptotanshinone protects cartilage against developing osteoarthritis through the miR-106a-5p", GLIS3 axis, 2018, pp.11, 170~179
140. Gu, R., "MicroRNA-9 regulates the development of knee osteoarthritis through the NF-κB1 pathway in chondrocytes", Medicine (Baltim.), 95, pp.e4315~ (2016)
141. Zhang, G., "MiR-502-5p inhibits IL-1β-induced chondrocyte injury by targeting TRAF2", Cell Immunol, 302, pp.50~57 (2016)
142. Hu, G., "MicroRNA-145 attenuates TNF-α-driven cartilage matrix degradation in osteoarthritis via direct suppression of MKK4", Cell Death Dis, 8, pp.e3140~ (2017)
143. Hu, J., "MiR-26a and miR-26b mediate osteoarthritis progression by targeting FUT4 via NF-κB signaling pathway", Int. J. Biochem. Cell Biol, 94, pp.79~88 (2018)
144. Wang, G., "MicroRNA-411 inhibited matrix metalloproteinase 13 expression in human chondrocytes", Am. J. Transl. Res, 7, pp.2000~2006 (2015)
145. Yang, F., "miRNA-411 regulates chondrocyte autophagy in osteoarthritis by targeting hypoxia-inducible factor 1 α(HIF-1α)", Med. Sci. Monit, 26, pp.e921155~ (2020)
146. Liu, W., "Upregulation of microRNA-27a inhibits synovial angiogenesis and chondrocyte apoptosis in knee osteoarthritis rats through the inhibition of PLK2", J. Cell Physiol, 234, pp.22972~22984 (2019)
147. Cai, C., "MiR-27a promotes the autophagy and apoptosis of IL-1β treatedarticular chondrocytes in osteoarthritis through PI3K", AKT, Aging (Albany NY), pp.2019, 11[DOI]

관련 논문AI추천